Max Healthcare Institute Limited has approved the grant of 2,15,000 stock options to eligible employees under its Employee Stock Option Scheme 2022. The decision was taken by the company's Nomination and Remuneration Committee during a meeting held on May 20, 2026. The scheme is compliant with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Grant Details

The committee approved the allotment in two distinct tranches. The first tranche consists of 90,000 stock options, while the second tranche comprises 1,25,000 stock options. Each stock option is convertible into one fully paid-up equity share with a face value of ₹10. The total number of equity shares covered by these options aggregates to 2,15,000.

Pricing and Vesting Schedule

The options have been assigned different exercise prices based on the specific tranche. The vesting for these options is subject to the fulfillment of pre-vesting conditions and will occur no earlier than one year and no later than five years from the date of the grant.

The options can be exercised within a period of three years from the respective date of vesting. The administration and implementation of the MHIL ESOP - 2022 are managed by the Nomination and Remuneration Committee of the company.

Max Healthcare Institute Limited has informed the stock exchanges that a petition has been filed before the National Company Law Tribunal (NCLT), Cuttack Bench, by BRS Capital Two Pte. Limited. The petition names Kalinga Hospital Ltd. (KHL), a subsidiary of Max Healthcare, and other shareholders from whom the company acquired a majority equity stake. The legal action was initiated under sections 241 and 242 of the Companies Act, 2013, alleging oppression and mismanagement of the affairs of KHL.

The disclosure follows the completion of Max Healthcare's acquisition of approximately 58.28% of the share capital of Kalinga Hospital Ltd. on May 18, 2026. The petition was listed for hearing on May 19, 2026, at 11:00 am IST. During the proceedings, the Hon'ble NCLT heard the submissions of the parties involved.

Litigation Details

The tribunal directed the parties to file concise written submissions based on the oral arguments advanced regarding the interim reliefs sought by the petitioner. Consequently, the matter has been reserved for orders by the NCLT. The next date of hearing for this case is scheduled for July 7, 2026.

Regarding the financial implications, the company stated that the outcome of the petition and its potential impact cannot be anticipated at this stage. The disclosure has been made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.